Category: From KIF1A.ORG

KIF1A.ORG Community, What if KIF1A treatment already existed? It could be on the shelves of your local pharmacy, or a drug created for a related disease like Parkinson’s or epilepsy. Are there FDA-approved treatments for other conditions that could bring relief to KAND patients living with progressive spasticity, uncontrolled seizures or painful neuropathy? We won’t…

KIF1A.ORG Community, Today we’re highlighting the exciting work we’re doing with Albany Molecular Research Inc. (AMRI) to support KIF1A.ORG’s therapeutic development efforts. This project was made possible by a Rising Tides grant awarded by The Child Neurology Foundation to support organizations during the COVID-19 pandemic.

KIF1A.ORG Community, We are thrilled to introduce you to two new staff members: Charlotte Klinepeter, Administrative Manager, and Aileen Lam, Science Communication Associate! Charlotte and Aileen bring valuable strengths and experiences to the organization and expand our capacity to accelerate our mission.

KIF1A.ORG Community, We’re excited to introduce one of our newest partners, the Bařinka Lab at Institute of Biotechnology of the Czech Academy of Sciences in the Czech Republic! Our partnership will enable the Bařinka Lab to collaborate with HNF Pharma Inc. and The Jackson Laboratory to study a potential drug therapy for KIF1A Associated Neurological…

KIF1A.ORG Community,  KIF1A.ORG is excited to share a series of announcements about recently funded projects powered to rapidly discover and develop treatments for people affected by KAND. First up: The McKenney Lab at University of California, Davis. Led by Richard McKenney, PhD, the McKenney Lab has long collaborated with KIF1A.ORG, and leads the field in…

Hello KIF1A.ORG community, Perhaps against all odds, 2020 has been a year of growth for the KIF1A community.

Dear KAND Families, It is with great hope for the future that I share this news—news with enormous impact on our mission to discover treatment for our loved ones living with KIF1A Associated Neurological Disorder. This morning Ovid Therapeutics announced a research collaboration with the Chung Lab at Columbia University. Ovid and Columbia have joined…

We are relentless. Today that “we” continues to grow.

A PDF of this statement can be downloaded here. The KIF1A.ORG Leadership Team is closely monitoring reports that governments and medical institutions will soon be implementing catastrophic and discriminatory pandemic ventilator allocation protocols, preventing life-saving access to ventilators.

Families and Friends of KIF1A.ORG: We are thrilled to announce Dr. Dominique Lessard has joined KIF1A.ORG’s Leadership Team as the organization’s Science Communication Director!